PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

BACKGROUND: The favourable safety profile and the increasing confidence with immune checkpoint inhibitors (ICIs) might have boosted their prescription in frail patients with short life expectancies, who usually are not treated with standard chemotherapy. METHODS: The present analysis aims to describ...

Descripción completa

Detalles Bibliográficos
Autores principales: Santini, Daniele, Zeppola, Tea, Russano, Marco, Citarella, Fabrizio, Anesi, Cecilia, Buti, Sebastiano, Tucci, Marco, Russo, Alessandro, Sergi, Maria Chiara, Adamo, Vincenzo, Stucci, Luigia S., Bersanelli, Melissa, Mazzaschi, Giulia, Spagnolo, Francesco, Rastelli, Francesca, Giorgi, Francesca Chiara, Giusti, Raffaele, Filetti, Marco, Marchetti, Paolo, Botticelli, Andrea, Gelibter, Alain, Siringo, Marco, Ferrari, Marco, Marconcini, Riccardo, Vitale, Maria Giuseppa, Nicolardi, Linda, Chiari, Rita, Ghidini, Michele, Nigro, Olga, Grossi, Francesco, De Tursi, Michele, Di Marino, Pietro, Pala, Laura, Queirolo, Paola, Bracarda, Sergio, Macrini, Serena, Gori, Stefania, Inno, Alessandro, Zoratto, Federica, Tanda, Enrica T., Mallardo, Domenico, Vitale, Maria Grazia, Talbot, Thomas, Ascierto, Paolo A., Pinato, David J., Ficorella, Corrado, Porzio, Giampiero, Cortellini, Alessio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223272/
https://www.ncbi.nlm.nih.gov/pubmed/34167578
http://dx.doi.org/10.1186/s12967-021-02937-9

Ejemplares similares

Ejemplares similares